CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL / SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You
CAR-T is a revolutionary therapy in CLL and other blood cancers. As part of the team led by Dr. Carl June at U. Penn, Dr. Joe Fraietta’s translational research has taken CAR-T from an exciting possibility to a lifesaving “living drug”. Don’t miss this opportunity to be able to learn about the latest CAR-T research and to ask your questions of one of CAR-T’s most innovative pioneers.
CAR-T Ed Forum: CAR-T Cell Therapy in CLL / SLL Recorded Wednesday, April 21, 2021 https://www.youtube.com/watch?v=8hQut-tEhB4 Continue to Session 4: CLL Society’s Overview of Programs and Services CLL Society Resources Download Slides CAR-T
CAR-T Ed ForumImmunotherapy: A New Paradigm for Treatment Recorded Wednesday, April 21, 2021 https://youtu.be/oNG2Wxw4iqY Continue to Session 3: CAR-T Cell Therapy in CLL / SLL CLL Society Resources Download Slides CAR-T Webpage CLL
To learn more information about how this revolutionary “living drug” works, the steps involved, insurance coverage, and eligibility, please read this short CAR-T infographic as well as other topics from the CAR-T Working Group.
CAR-T is an option for CLL. Its expense and complexity make it inaccessible to many. Making CAR-T cells in the body (in vivo) changes everything.
By never freezing the locally produced CAR-T cells, disappointing response rates for relapsed/refractory CLL and Richter’s Syndrome patients are greatly improved
CAR-T is an effective but underused option in cancer. Successful engineering of CAR-T cells in vivo in nonhuman primates has now been achieved.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
